{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:24:01Z","timestamp":1793823841668,"version":"4.6.1"},"reference-count":75,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T00:00:00Z","timestamp":1706140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013394","name":"REGENXBIO Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32GM113846-10"],"award-info":[{"award-number":["5T32GM113846-10"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS062158"],"award-info":[{"award-number":["NS062158"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.omtm.2024.101201","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T12:55:54Z","timestamp":1706619354000},"page":"101201","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-8681","authenticated-orcid":false,"given":"Miles C.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitha R.","family":"Belur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea D.","family":"Karlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Erlanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Furcich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley F.","family":"Kitto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A.","family":"Fairbanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwi Hye","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Buss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-0902","authenticated-orcid":false,"given":"R. Scott","family":"McIvor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2024.101201_bib1","doi-asserted-by":"crossref","first-page":"7888","DOI":"10.3390\/ijms22157888","article-title":"Differences in MPS I and MPS II Disease Manifestations","volume":"22","author":"Hampe","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101201_bib2","series-title":"The Online Metabolic and Molecular Bases of Inherited Disease","article-title":"The Mucopolysaccharidoses","author":"Neufeld","year":"2019"},{"key":"10.1016\/j.omtm.2024.101201_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.omtm.2024.101201_bib4","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.omtm.2024.101201_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10545-008-0878-x","article-title":"Neurological findings in Hunter disease: pathology and possible therapeutic effects reviewed","volume":"31","author":"Al Sawaf","year":"2008","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2024.101201_bib6","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymgme.2007.03.003","article-title":"Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II","volume":"91","author":"Garcia","year":"2007","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101201_bib7","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ymgme.2006.09.001","article-title":"A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome)","volume":"90","author":"Muenzer","year":"2007","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101201_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib11","first-page":"65","article-title":"Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients","volume":"3","author":"Parini","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2024.101201_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101201_bib13","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2022.07.017","article-title":"Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2\/3 randomized study","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101201_bib14","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib15","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.omtm.2024.101201_bib16","first-page":"81","article-title":"Effectiveness of Early Hematopoietic Stem Cell Transplantation in Preventing Neurocognitive Decline in Mucopolysaccharidosis Type II: A Case Series","volume":"41","author":"Selvanathan","year":"2018","journal-title":"JIMD Rep."},{"key":"10.1016\/j.omtm.2024.101201_bib17","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.3390\/ijms23094854","article-title":"Current and Future Treatment of Mucopolysaccharidosis (MPS) Type II: Is Brain-Targeted Stem Cell Gene Therapy the Solution for This Devastating Disorder?","volume":"23","author":"Horgan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101201_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib19","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis of AAV Serotypes 1\u20139 Mediated Gene Expression and Tropism in Mice After Systemic Injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0167-5273(02)00554-5","article-title":"Adeno-associated virus (AAV) vectors achieve prolonged transgene expression in mouse myocardium and arteries in\u00a0vivo: a comparative study with adenovirus vectors","volume":"90","author":"Vassalli","year":"2003","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.omtm.2024.101201_bib21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/17425247.2015.966682","article-title":"Gene Therapy for Neurologic Manifestations of Mucopolysaccharidoses","volume":"12","author":"Wolf","year":"2015","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.omtm.2024.101201_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nbt.1515","article-title":"Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes","volume":"27","author":"Foust","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2024.101201_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtm.2024.101201_bib25","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/hmg\/ddl038","article-title":"Correction of Hunter syndrome in the MPSII mouse model by AAV2\/8-mediated gene delivery","volume":"15","author":"Cardone","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.omtm.2024.101201_bib26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajhg.2009.07.011","article-title":"IDS Crossing of the Blood-Brain Barrier Corrects CNS Defects in MPSII Mice","volume":"85","author":"Polito","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omtm.2024.101201_bib27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.omtm.2018.07.005","article-title":"Targeting Root Cause by Systemic scAAV9-hIDS Gene Delivery: Functional Correction and Reversal of Severe MPS II in Mice","volume":"10","author":"Fu","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101201_bib28","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1089\/hum.2016.184","article-title":"Prevention of Neurocognitive Deficiency in Mucopolysaccharidosis Type II Mice by Central Nervous System\u2013Directed, AAV9-Mediated Iduronate Sulfatase Gene Transfer","volume":"28","author":"Laoharawee","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib29","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2016.101","article-title":"Delivery of an Adeno-Associated Virus Vector into Cerebrospinal Fluid Attenuates Central Nervous System Disease in Mucopolysaccharidosis Type II Mice","volume":"27","author":"Hinderer","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.omtm.2024.101201_bib31","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in\u00a0vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib32","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/hum.1996.7.3-283","article-title":"Preclinical Studies of Lymphocyte Gene Therapy for Mild Hunter Syndrome (Mucopolysaccharidosis Type II)","volume":"7","author":"Braun","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.1996.7.4-537","article-title":"Retroviral-Mediated Transfer of the Iduronate-2-Sulfatase Gene into Lymphocytes for Treatment of Mild Hunter Syndrome (Mucopolysaccharidosis Type II)","volume":"7","author":"Whitley","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib34","article-title":"Non-invasive intravenous administration of AAV9 transducing iduronate sulfatase leads to global metabolic correction and prevention of neurologic deficits in a mouse model of Hunter syndrome","volume":"34","author":"Laoharawee","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2024.101201_bib35","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.ymthe.2018.03.002","article-title":"Dose-Dependent Prevention of Metabolic and Neurologic Disease in Murine MPS II by ZFN-Mediated In\u00a0Vivo Genome Editing","volume":"26","author":"Laoharawee","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib36","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10545-007-0641-8","article-title":"The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)","volume":"30","author":"Garcia","year":"2007","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2024.101201_bib37","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/clinchem\/43.8.1325","article-title":"Diagnosis of lysosomal storage disorders: evaluation of lysosome-associated membrane protein LAMP-1 as a diagnostic marker","volume":"43","author":"Meikle","year":"1997","journal-title":"Clin. Chem."},{"key":"10.1016\/j.omtm.2024.101201_bib38","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/hum.2021.252","article-title":"Minimum Effective Dose to Achieve Biochemical Correction with Adeno-Associated Virus Vector-Mediated Gene Therapy in Mice with Pompe Disease","volume":"33","author":"Han","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101201_bib40","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101201_bib41","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.mt.6300334","article-title":"Prolonged Susceptibility to Antibody-mediated Neutralization for Adeno-associated Vectors Targeted to the Liver","volume":"16","author":"Murphy","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib42","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2024.101201_bib43","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101201_bib44","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2024.101201_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.omtm.2020.10.014","article-title":"Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector","volume":"19","author":"Bobo","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101201_bib46","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of Neurological Disease of Mucopolysaccharidosis IIIB in Adult Mice by rAAV9 Trans-Blood\u2013Brain Barrier Gene Delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1038\/mt.2014.135","article-title":"Intrathecal Gene Therapy Corrects CNS Pathology in a Feline Model of Mucopolysaccharidosis I","volume":"22","author":"Hinderer","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib48","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1172\/JCI59261","article-title":"Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration","volume":"121","author":"Malato","year":"2011","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2024.101201_bib49","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.666666","article-title":"T Cell-Mediated Immune Responses to AAV and AAV Vectors","volume":"12","author":"Ertl","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2024.101201_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1089\/hum.2017.048","article-title":"AAV: An Overview of Unanswered Questions","volume":"28","author":"Berns","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2024.101201_bib53","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia","volume":"385","author":"George","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib54","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708730","article-title":"Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms","volume":"10","author":"Gleitz","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2014.00042","article-title":"Biodistribution of adeno-associated virus serotype 9 (AAV9) vector after intrathecal and intravenous delivery in mouse","volume":"8","author":"Schuster","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.omtm.2024.101201_bib56","article-title":"Intravenous delivery for treatment of mucopolysaccharidosis type I: A comparison of AAV serotypes 9 and rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.omtm.2024.101201_bib57","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib58","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2013.09.008","article-title":"High-dose enzyme replacement therapy in murine Hurler syndrome","volume":"111","author":"Ou","year":"2014","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.omtm.2024.101201_bib59","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/mt.2009.87","article-title":"Systemic Correction of Storage Disease in MPS I NOD\/SCID Mice Using the Sleeping Beauty Transposon System","volume":"17","author":"Aronovich","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.omtm.2020.09.012","article-title":"Ex\u00a0Vivo Gene Therapy Treats Bone Complications of Mucopolysaccharidosis Type II Mouse Models through Bone Remodeling Reactivation","volume":"19","author":"Wada","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2024.101201_bib61","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/hum.2022.141","article-title":"Phenotypic Correction of Murine Mucopolysaccharidosis Type II by Engraftment of Ex\u00a0Vivo Lentiviral Vector-Transduced Hematopoietic Stem and Progenitor Cells","volume":"33","author":"Smith","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.618360","article-title":"Comparative Effectiveness of Intracerebroventricular, Intrathecal, and Intranasal Routes of AAV9 Vector Administration for Genetic Therapy of Neurologic Disease in Murine Mucopolysaccharidosis Type I","volume":"14","author":"Belur","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.omtm.2024.101201_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.809118","article-title":"Gene Therapy Advances: A Meta-Analysis of AAV Usage in Clinical Settings","volume":"8","author":"Au","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib64","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1089\/gen.40.09.04","article-title":"Gene Therapy: It Is Time to Talk about High-Dose AAV","volume":"40","author":"Paulk","year":"2020","journal-title":"Genet. Eng. Biotechnol. News"},{"key":"10.1016\/j.omtm.2024.101201_bib65","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2024.101201_bib66","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector\u2013Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib67","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2024.101201_bib68","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","article-title":"Clinical course of sly syndrome (mucopolysaccharidosis type VII)","volume":"53","author":"Monta\u00f1o","year":"2016","journal-title":"J.\u00a0Med. Genet."},{"key":"10.1016\/j.omtm.2024.101201_bib69","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3390\/ijms18020441","article-title":"A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments","volume":"18","author":"Stirnemann","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101201_bib70","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/nan.12587","article-title":"Review: Danon disease: Review of natural history and recent advances","volume":"46","author":"Cenacchi","year":"2020","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.omtm.2024.101201_bib71","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012693","article-title":"Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy","volume":"23","author":"Piechnik","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtm.2024.101201_bib72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(80)90515-4","article-title":"Intrathecal morphine in mice: A new technique","volume":"67","author":"Hylden","year":"1980","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.omtm.2024.101201_bib73","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0169-409X(03)00101-7","article-title":"Spinal delivery of analgesics in experimental models of pain and analgesia","volume":"55","author":"Fairbanks","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.omtm.2024.101201_bib74","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1023\/A:1012763026526","article-title":"A fluorimetric enzyme assay for the diagnosis of MPS II (Hunter disease)","volume":"24","author":"Voznyi","year":"2001","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2024.101201_bib75","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1037\/h0077579","article-title":"Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat","volume":"93","author":"Barnes","year":"1979","journal-title":"J.\u00a0Comp. Physiol. Psychol."}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050124000172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:37Z","timestamp":1778867677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050124000172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2329050124000172"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101201","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2024.101201","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"101201"}}